Laura Chico
Stock Analyst at Wedbush
(1.29)
# 3,248
Out of 4,818 analysts
211
Total ratings
29.58%
Success rate
-13.15%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EWTX Edgewise Therapeutics | Maintains: Outperform | $43 | $14.80 | +190.64% | 10 | Apr 21, 2025 | |
| TRML Tourmaline Bio | Maintains: Outperform | $42 → $43 | $17.66 | +143.56% | 2 | Mar 14, 2025 | |
| VIGL Vigil Neuroscience | Maintains: Outperform | $24 → $13 | $1.81 | +620.22% | 9 | Mar 14, 2025 | |
| GOSS Gossamer Bio | Reiterates: Outperform | $4 | $0.90 | +345.78% | 4 | Mar 14, 2025 | |
| OVID Ovid Therapeutics | Maintains: Outperform | $4 → $3 | $0.32 | +829.94% | 2 | Mar 12, 2025 | |
| DNTH Dianthus Therapeutics | Reiterates: Outperform | $36 | $21.75 | +65.52% | 6 | Mar 12, 2025 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $27 → $28 | $5.18 | +440.54% | 9 | Mar 12, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $30 → $29 | $17.54 | +65.34% | 14 | Mar 3, 2025 | |
| SAGE Sage Therapeutics | Reiterates: Neutral | $6 | $7.68 | -21.88% | 9 | Feb 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $157 → $147 | $102.88 | +42.88% | 9 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 → $48 | $37.74 | +27.19% | 12 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $3.57 | +348.81% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $12 | $1.59 | +654.72% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $38 | $22.60 | +68.14% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $4 | $2.30 | +73.91% | 3 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $25 | $16.59 | +50.69% | 9 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $2.24 | +882.14% | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $210 → $205 | $118.01 | +73.71% | 16 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $48 | $36.75 | +30.61% | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $49 | $37.59 | +30.35% | 8 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $3.51 | +99.43% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $15.22 | +70.88% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $4.84 | +127.51% | 13 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $13.68 | +207.02% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $17 | $9.51 | +78.76% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $41 | $2.76 | +1,388.20% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $31 | $14.99 | +106.80% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.30 | +3,569.11% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $4.05 | +23.46% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $61.79 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $1.82 | +175.48% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $21.47 | +591.66% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $7.34 | +9,709.26% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $21.84 | +1,182.05% | 1 | Apr 21, 2017 |
Edgewise Therapeutics
Apr 21, 2025
Maintains: Outperform
Price Target: $43
Current: $14.80
Upside: +190.64%
Tourmaline Bio
Mar 14, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $17.66
Upside: +143.56%
Vigil Neuroscience
Mar 14, 2025
Maintains: Outperform
Price Target: $24 → $13
Current: $1.81
Upside: +620.22%
Gossamer Bio
Mar 14, 2025
Reiterates: Outperform
Price Target: $4
Current: $0.90
Upside: +345.78%
Ovid Therapeutics
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $0.32
Upside: +829.94%
Dianthus Therapeutics
Mar 12, 2025
Reiterates: Outperform
Price Target: $36
Current: $21.75
Upside: +65.52%
Astria Therapeutics
Mar 12, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $5.18
Upside: +440.54%
Apellis Pharmaceuticals
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $17.54
Upside: +65.34%
Sage Therapeutics
Feb 12, 2025
Reiterates: Neutral
Price Target: $6
Current: $7.68
Upside: -21.88%
Neurocrine Biosciences
Feb 7, 2025
Maintains: Outperform
Price Target: $157 → $147
Current: $102.88
Upside: +42.88%
Jan 13, 2025
Reiterates: Neutral
Price Target: $46 → $48
Current: $37.74
Upside: +27.19%
Dec 13, 2024
Initiates: Outperform
Price Target: $16
Current: $3.57
Upside: +348.81%
Nov 8, 2024
Maintains: Outperform
Price Target: $19 → $12
Current: $1.59
Upside: +654.72%
Nov 8, 2024
Maintains: Neutral
Price Target: $30 → $38
Current: $22.60
Upside: +68.14%
Oct 23, 2024
Downgrades: Neutral
Price Target: $29 → $4
Current: $2.30
Upside: +73.91%
Oct 9, 2024
Maintains: Outperform
Price Target: $17 → $25
Current: $16.59
Upside: +50.69%
Oct 3, 2024
Initiates: Outperform
Price Target: $22
Current: $2.24
Upside: +882.14%
Sep 23, 2024
Maintains: Neutral
Price Target: $210 → $205
Current: $118.01
Upside: +73.71%
Aug 14, 2024
Maintains: Neutral
Price Target: $40 → $48
Current: $36.75
Upside: +30.61%
Aug 9, 2024
Maintains: Outperform
Price Target: $50 → $49
Current: $37.59
Upside: +30.35%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $3.51
Upside: +99.43%
Aug 2, 2024
Maintains: Outperform
Price Target: $30 → $26
Current: $15.22
Upside: +70.88%
Aug 2, 2024
Reiterates: Outperform
Price Target: $11
Current: $4.84
Upside: +127.51%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $13.68
Upside: +207.02%
Jul 11, 2024
Reiterates: Outperform
Price Target: $17
Current: $9.51
Upside: +78.76%
Jun 6, 2024
Reiterates: Outperform
Price Target: $41
Current: $2.76
Upside: +1,388.20%
May 9, 2024
Maintains: Outperform
Price Target: $35 → $31
Current: $14.99
Upside: +106.80%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.30
Upside: +3,569.11%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $4.05
Upside: +23.46%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $61.79
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $1.82
Upside: +175.48%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $21.47
Upside: +591.66%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $7.34
Upside: +9,709.26%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $21.84
Upside: +1,182.05%